Voyager & Neurocrine Team Up for Gene Therapies in Parkinson's & More
Voyager Therapeutics and Neurocrine Biosciences have teamed up to advance gene therapies for neurological diseases. The collaboration, advised on antitrust and competition issues by an unnamed lawyer, involves Voyager's GBA1 gene therapy program for Parkinson's disease and three new programs. The deal sees Neurocrine funding the development program and paying Voyager an up-front consideration of $175 million, including a $39 million equity investment from Neurocrine. Additionally, Voyager could earn up to $1.5 billion in potential development milestone payments from Neurocrine.
This collaboration allows both companies to expand their gene therapy pipelines. Voyager gains financial support and the potential for significant milestone payments from Neurocrine, while Neurocrine gains access to promising neurological disease programs.
